Expression of EZH2 in uveal melanomas patients and associations with prognosis

Ying Cheng; Ying Li; Xin Huang; Wenbin Wei; Yi Qu

doi:10.18632/oncotarget.19462

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Expression of EZH2 in uveal melanomas patients and associations with prognosis

Ying Cheng, Ying Li, Xin Huang, Wenbin Wei and Yi Qu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:76423-76431. https://doi.org/10.18632/oncotarget.19462

Metrics: PDF 1435 views | HTML 2052 views | ?

Abstract

Ying Cheng1, Ying Li1, Xin Huang1, Wenbin Wei2 and Yi Qu1

1Department of Geriatrics, Qilu Hospital of Shandong University, Jinan, China

2Beijing Tongren Hospital, Capital Medical University, Beijing Tongren Eye Center, Beijing Ophthalmology and Visual Science Key Laboratory, Beijing, China

Correspondence to:

Yi Qu, email: [email protected]

Keywords: uveal melanomas, EZH2, ki-67, immunohistochemistry, prognosis

Received: September 14, 2016 Accepted: June 13, 2017 Published: July 22, 2017

ABSTRACT

Purpose: To analyze the prognostic value and potential target for therapeutic intervention of enhancer of zeste homologue 2 (EZH2) in uveal melanomas (UM) patients.

Method: We analyzed EZH2 expression in 89 primary UM patients by immuno- histochemistry to observe the clinicopathological and prognostic value of EZH2.

Results: The high levels of mitoses count and Ki67 labeling index had significant correlation with overexpression EZH2 (R = 0.408, P<0.0001; R = 0.72, P<0.0001). High level of EZH2 expression was significantly associated with increased risk of distant metastasis by the Cox proportional hazards regression model (multivariate hazard ratio: 2.12; log rank P = 0.037) and shorter UM-specific survival (multivariate hazard ratio: 3.92; log rank P = 0.036).

Conclusion: Our critical finding is that overexpression EZH2 in UM can be served as predictive marker and is associated with adverse clinical outcomes. Further observation of EZH2 as a potential therapeutic target in UM is necessary.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19462

Publication Alerts

Research Papers:

Expression of EZH2 in uveal melanomas patients and associations with prognosis

Abstract